Bevacizumab (avastin) therapy for idiopathic macular telangiectasia type II

Retina

Volumn 29, Issue 1, 2009, Pages 27-32

  Kovach, Jaclyn L ^a   Rosenfeld, Philip J ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; VASCULOTROPIN A; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CLINICAL ARTICLE; EYE; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2; MALE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; RETINA MACULA LUTEA; RETINA MACULOPATHY; RETINAL THICKNESS; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS; CASE REPORT; DRUG ANTAGONISM; DRUG EFFECT; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA BLOOD VESSEL; RETINA DISEASE; TELANGIECTASIA;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RETINAL DISEASES; RETINAL VESSELS; RETROSPECTIVE STUDIES; TELANGIECTASIS; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 61549122342     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31818ba9de     Document Type: Article

References (24)

1. Gass JDM. A fluorescein angiographic study of macular dysfunction secondary to retinal vascular disease. V. Retinal tel-angiectasis. Arch Ophthalmol 1968;80:592-605.
2. Gass JD, Oyakawa RT. Idiopathic juxtafoveolar retinal telan-giectsis. Arch Ophthalmol 1982;100:769-780.
3. Gass JD, Blodi BA. Idiopathic juxtafoveolar retinal telangiec-tasis: update of classification and follow-up study. Ophthalmology 1993;100:1536-1546.
4. Yannuzzi LA, Bardal AMC, Freund KB, Chen KJ, Eandi CM, Blodi B. Idiopathic macular telangiectasia. Arch Ophthalmol 2006;124:450-460.
5. Park DM, Schatz H, McDonald HR, Johnson RN. Grid laser photocoagulation for macular edema in bilateral juxtafoveal telangiectasis. Ophthalmology 1997;104:1838-1846.
6. Berger AS, McCuen BW II, Brown GC, Brownlow RL Jr. Surgical removal of subfoveal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Retina 1997;17:94-98.
7. Shukla D, Singh J, Kolluru CM, Kim R, Namperumalsamy P. Transpupillary thermotherapy for subfoveal neovasculariza-tion secondary to group 2A idiopathic juxtafoveolar telangi-ectasis. Am J Ophthalmol 2004;138:147-149.
8. Nachiappan K, Shanmugam MP. Treatment of CNVM secondary to idiopathic juxtafoveal retinal telangiectasis by transpupillary thermotherapy. Am J Ophthalmol 2005;139:577-578. 9. Snyers B, Verougstraete C, Postelmans L, Leys A, Hykin P. Photodynamic therapy of subfoveal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis. Am J Ophthalmol 2004;137:812-819.
9. Hershberger VS, Hutchins RK, Laber PW. Photodynamic therapy with verteporfin for subretinal neovascularization secondary to bilateral idiopathic acquired juxtafoveolar telangiectasis. Ophthalmic Surg Lasers Imaging 2003;34:318 -320.
10. Potter MJ, Szabo SM, Chan EY, Morris AH. Photodynamic therapy of a subretinal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis. Am J Ophthal-mol 2002;133:149-151.
11. Alldredge CD, Garretson BR. Intravitreal triamcinolone for the treatment of idiopathic juxtafoveal telangiectasis. Retina 2003;23:113-116.
12. Smithen LM, Spaide RF. Photodynamic therapy and intravit-real triamcinolone for a subretinal neovascularization in bilateral idiopathic juxtafoveal telangiectasis. Am J Ophthalmol 2004;138:884-885.
13. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-4599.
14. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.
15. Jorge R, Cost RA, Calucci D, Scott IU. Intravitreal bevaci-zumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangi-ectasis. Graefes Arch Clin Exp Ophthalmol 2007;245:1045- 1048
16. Shanmugam MP, Mythri HM, Shetty NS. Inravitreal bevaci-zumab for parafoveal telangiectasia-associated choroidal neo-vascular membrane. Indian J Ophthalmol 2007;55:490-491.
17. Charbel Issa P, Holz FG, Scholl HP. Findings in fluorescein angiography and optical coherence tomography after intravit-real bevacizumab in type 2 idiopathic macular telangiectasia. Ophthalmology 2007;114:1736-1742.
18. Ruys J, De Laey JJ, Vanderhaeghen Y, Van Aken EH. Intra-vitreal bevacizumab (Avastin) for the treatment of bilateral acquired juxtafoveal retinal telangiectasis associated with cho-roidal neovascular membrane. Eye 2007;21:1433-1434.
19. Maia OO Jr, Bonanomi MT, Takahashi WY, Nascimento VP, Takahashi BS. Intravitreal bevacizumab for foveal detachment in idiopathic perifoveal telangiectasia. Am J Ophthalmol 2007; 144:296-299.
20. Mandal S, Venkatesh P, Abbas Z, et al. Intravitreal bevaci-zumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia. Graefes Arch Clin Exp Ophthalmol 2007;245:1825-1829.
21. Gamulescu MA, Walter A, Sachs H, Helbig H. Bevacizumab in the treatment of idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol 2008;246:1189-1193.
22. Querques G, Delle Noci N. Re: optical coherence tomography findings in nonproliferative group 2a idiopathic juxtafoveal retinal telangiectasis. Retina 2008;28:368-369.
23. Cohen SM. Reply to above. Retina 2008;28:369-370.
24. Yourey PA, Gohari S, Alderson RF. Vascular endothelial cell growth factors promote in the in vitro development of rat photoreceptor cells. J Neurosci 2000;20:6781- 6788.